Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM101 in IgA Nephropathy
NCT02605525Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- Nov 2016
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 2, randomised, double-blind trial of valziflocept in immunoglobulin A nephropathy (IgAN) (3 arms), sponsored by Takeda. Primary endpoint: Percent change in proteinuria from Baseline to Week 24. Planned start Dec 2015; status: withdrawn.
02
Drugs
valziflocept
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02605525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605525.